Non-Small Cell Lung Cancer (NSCLC)

At a minimum follow-up of 3 years, an improvement in overall survival was seen in patients with metastatic non–small cell lung cancer treated with nivolumab and ipilimumab in combination with chemotherapy.

Results from the phase 3 PEARLS/KEYNOTE-091 trial showed improved disease-free survival with pembrolizumab vs placebo for patients with completely resected early-stage non–small cell lung cancer, without regard surgical treatment, extent of disease, or adjuvant chemotherapy.

The 5-year analysis of the phase 3 CheckMate 227 trial showed consistent, long-term survival with nivolumab plus ipilimumab for metastatic non–small cell lung cancer.

In a MET-unselected population of PD-L1–positive non–small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity.

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.

Patients with EGFR exon 20 insertion–positive non–small cell lung cancer may have antitumor response with the selective EGFR inhibitor CLN-081 following multiple prior lines of treatment.

The combination of pembrolizumab plus ramucirumab resulted in better overall survival compared with the standard of care regimens despite similar response rates, according to results of a Lung-MAP substudy presented at 2022 ASCO.

The KRAS G12C inhibitor adagrasib demonstrated an objective response rate of 43% and disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The phase 3 ALTER 0303 trial demonstrated that although patients with non–small cell lung cancer and liver metastases have a worse prognosis than those without, treatment with anlotinib may result in better progression-free survival vs a placebo.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Final end point analysis of the GEMSTONE-301 trial confirmed that patients with stage III non–small cell lung cancer experienced significant clinical benefit and promising efficacy following consolidation therapy with sugemalimab monotherapy.

Results from the phase 3 CheckMate 816 trial show patients with resectable non¬–small cell lung cancer had improved event-free survival when treated with neoadjuvant nivolumab plus chemotherapy vs chemotherapy alone.

The primary end point of progression-free survival was not met in the phase 3 SKYSCRAPER-1 trial assessing tiragolumab plus atezolizumab for patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.

Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.

In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.

In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.

Patients with HER2-mutated metastatic non–small cell lung cancer who have previously received treatment with systemic therapies appear to benefit from treatment with fam-trastuzumab deruxtecan-nxki, which received priority review from the FDA.

Patients with early stage non–small cell lung cancer and impaired pulmonary function could potentially benefit from treatment with stereotactic body radiotherapy.

Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

Patients with non–small cell lung cancer harboring a MET exon 14 skipping mutation appeared to derive durable efficacy following treatment with SCC244.

Adjuvant durvalumab combined with different monoclonal antibodies led to enriched major pathologic responses in early-stage non–small cell lung cancer.

Results of a phase 3 trial comparing neoadjuvant nivolumab plus chemotherapy denoted benefit vs chemotherapy alone for patients with resectable non-small cell lung cancer.

Updated data from the phase 1/2 CodeBreaK 100 trial of sotorasib provide the longest follow-up of a KRAS G12C inhibitor in non–small cell lung cancer.

Data presented from the 4-year follow-up to the phase 3 KEYNOTE-042 trial display continuous survival benefit of pembrolizumab vs chemotherapy in Chinese patients with untreated non–small cell lung cancer.

Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.

While quality of life did not improve with esophageal-sparing intensity-modulated radiotherapy, patients with stage III/IV non–small cell lung cancer did experience a reduction in symptomatic esophagitis.

A biologics license application for sintilimab plus chemotherapy in first-line nonsquamous non–small cell lung cancer was not approved by the FDA and a complete response letter was issued to the drug developer.

The FoundationOne CDx diagnostic was approved as a companion diagnostic to help identify EGFR 19 deletions or exon 21 alterations in non–small cell lung cancer.